NEW YORK, Nov. 18
Reportlinker.com announces that a new market research report is available in its catalogue.
Alzheimer's and Parkinson's Diseases - A Global Update of Market Trends & Opportunities
Advertisement
http://www.reportlinker.com/p0164262/Alzheimer's-and-Parkinson's-Diseases---A-Global-Update-of-Market-Trends--Opportunities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire
Advertisement
Alzheimer's disease (AD) and Parkinson's disease (PD) are the two important segments in neurodegenerative disorders market. These disorders represent unmet medical needs, as well as under diagnosed categories. However, this unmet requirement offers substantial opportunities for next generation therapies. Though there is no curative medicine available at present, medications that provide partial relief from symptoms have gained momentum in the recent past. The industry has crossed some milestones in recent years, although major breakthroughs are still in pipeline.
These and other market data and trends are presented in "Alzheimer's and Parkinson's Diseases: A Global Update of Market Trends & Opportunities" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.
ALZHEIMER'S AND PARKINSON'S DISEASES BMR-1062
CONTENTS
1. METHODOLOGY 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Quantitative Techniques & Reporting Level 3
2. OUTLOOK 4
Current and Future Analysis 4
3. NEURODEGENERATIVE DISEASES MARKET - A BRIEF OVERVIEW 4
Key Brands in NDD Market 4
Factors Affecting Market 6
Major Growth Drivers 6
Major Growth Inhibitors 6
Market Trends 6
High Prevalence Rates Drive Market Growth 6
Rapid Growth of Ageing Population 6
Price Hikes and Government Caps 6
Combination Therapy Gaining Ground 7
Research & Development 7
Future Holds Promise 7
4. ALZHEIMER'S MARKET OVERVIEW 8
A Peek into Anti-AD Drug Market 8
Impact of Dementia 8
Epidemiology 9
Patient Growth Drivers 10
Demographics Spell Opportunities 10
High Growth Rates for AD Drugs 11
The Impact of Aricept 11
Epic of NMDARA 11
Strengths 12
Weaknesses 12
Future Therapies 13
How Successful will the Late Stage Therapies be? 13
Alternative Drug Delivery Technologies Gaining Ground 13
Transdermal Patch 13
Domination of Acetyl Cholinesterase Inhibitors 14
Dramatic Changes in Market Lie Ahead 14
Advances in Next-Generation Treatments 14
Beta Amyloid Hypothesis 14
Growth Drivers 15
Ageing Baby Boomers Drive AD Market 15
New Hypothesis Enables Effective Treatment 15
Unmet Medical Needs Drive Market Growth 15
Growth Inhibitors 15
Link with Other Aliments 15
Misdiagnosis 16
Patient Awareness 16
Medical Refunds 16
Competitive Landscape 16
Pharmaceutical Majors Rule the Market 16
Eisai/Pfizer 17
Novartis 17
Shire/Johnson & Johnson 17
Forest 17
Ipsen and UCB 17
Compounds in Pipeline 18
There are many compounds in pipeline for the treatment of AD 18
Outlook for AD Drugs Market 19
5. PARKINSON'S DISEASE MARKET OVERVIEW 19
An Alluring Market 19
Prevalence 19
Current Treatments 20
New Medicines on the Horizon 20
New Findings 21
Product Launches Through 2009 21
Dominance of Dopamine Agonists 21
Revival Revels in Other Anti-PD Drugs Segment 21
COMT Inhibitors Growing Fastest 21
Key Market Drivers 22
Rising Awareness Magnifies Patient Base 22
Emergence of Dopamine Agonists as First Line Treatment Drives
Market- Growth 22
The Debut of Stalevo 22
Unmet Clinical Needs Show Mammoth Prospects 22
Key Market Inhibitors 22
Limitations of Existing Medicines Inhibit Market Growth 22
Under-Diagnosis Restrains Market Potential 23
Generic Competition from L-Dopa and Carbidopa Curbs Market
Growth 23
Restricted Term of Dopamine Agonists Usage Delays Market Growth 23
6. PRODUCT FACTS 24
1. Anti-Alzheimer's Disease Drugs 24
A. Cholinesterase Inhibitors 24
B. NMDARA 24
2. Anti-Parkinson's Disease Drugs 24
A. Dopaminergic Agents (Levodopa/ Carbidopa) 24
B. Dopamine Agonists 25
C. Other PD Drugs (Include COMT Inhibitors, MOA-B
Inhibitors, and Dopamine Amplifiers) 25
i. COMT Inhibitors 25
ii. MAO-B Inhibitors 25
iii. Dopamine Amplifiers 26
7. FUTURE THERAPIES 26
Alzheimer's Disease 26
Key Pipeline Products 27
Phenserine 27
Ropern 27
Alzhemed 27
MEM 1003 27
Ampakine Compounds 28
Other key pipeline products for the Alzheimer's disease-
treatment. 28
Parkinson's Disease 28
Key Pipeline Products 28
Adenosine A2a Antagonist 28
Spheramine® 29
Safinamide 29
O-1369 29
Other key pipeline products for the Parkinson's disease
treatment. 30
8. NEW FINDINGS 30
Risedronate Minimizes Risk of Hip Fractures in PD Patients 30
Researchers Identify New Genes Responsible for AD 30
Researchers Establish a New Link Between Loneliness and AD 30
Researchers Try to Identify Early Stages of AD 31
SORL1 - The New Gene Found to be Responsible for AD 31
9. CORPORATE DEVELOPMENTS 32
Eisai Acquires MGI Pharma 32
Eli Lilly Begins Phase III Clinical Trial of Alzheimer's
Disease Treatment 32
Merz Licenses Anti-Alzheimer's Drug Technology from TAU 32
Eisai Acquires Morphotek 32
Transition Therapeutics Acquires NeuroMedix 32
Evotec Teams Up with Boehringer Ingelheim 33
Siemens Signs Partnership Agreement with Wyeth 33
Digilab Receives Notice of Allowance for New Alzheimer's
Biomarker 33
Pfizer Joins Forces with Genizon 33
Intellect Signs Licensing Agreement with IBL 33
Boehringer Ingelheim Signs R&D Agreement with Ablynx 34
Avicena Teams Up with NINDS for Phase III Trial of PD-02 34
Exelon Patch Gets EU Approval 34
10. MAJOR PLAYERS 35
Boehringer Ingelheim (Germany) 35
Bristol-Myers Squibb Co. (USA) 35
Eisai, Inc. (USA) 35
Eli Lilly and Company (USA) 35
Forest Pharmaceuticals (USA) 36
GlaxoSmithKline PLC (UK) 36
H. Lundbeck A/S (Denmark) 36
Merz Pharmaceuticals GMBH (Germany) 36
Novartis AG (Switzerland) 36
Ortho-McNeil Neurologics, Inc. (USA) 37
Pfizer Inc (US) 37
Roche (Switzerland) 37
Shire Pharmaceuticals Group PLC (UK) 38
Valeant Pharmaceuticals International (USA) 38
11. GLOBAL MARKET ANALYTICS 39
12. THE UNITED STATES 49
AD Market Overview 49
Approval of Cholinesterase Inhibitors for MCI to Drive Market 49
Competitive Landscape 49
Status of AD Drugs 50
New Products in Clinical Trials 51
Prevalence 51
PD Therapies Market 51
Levodopa/Carbidopa on Declining Spree 51
Competition 52
Patent Expiry Status 52
Patent Expiry Status of Parkinson's Disease Drugs in the US 52
New Brands and Pipeline Analysis 52
13. CANADA 54
14. JAPAN 55
15. EUROPE 56
a. Germany 59
b. France 60
c. The United Kingdom 61
d. Italy 62
e. Spain 63
f. Rest of Europe 64
16. REST OF WORLD 65
EXHIBITS
Table 1: Percentage Breakdown of Leading Drugs in the Global
Neurodegenerative Disease Market - 2004
Table 2: World Alzheimer's Disease Prevalence by
Country/Region for the Period 2007 - 2010: (Number of Patients
in Thousands)
Table 3: Alzheimer's Disease Prevalence in Top Seven
Countries (US, Japan, Germany, France, UK, Italy, and Spain)
for the Period 2007 - 2010 (Number of Patients in Thousands)
Table 4: Percentage Breakdown of Leading Brands in the Global
Anti-Alzheimer's Drug Market - 2005
Table 5: World Parkinson's Disease Prevalence by
Country/Region for the Period 2007 - 2010 (Number of Patients
in Thousands)
Table 6: Global Anti-Alzheimer's and Anti-Parkinson's Disease
Drugs Market by Region for the Period 2007-2015 (Sales in US$
Million)
Table 7: Percentage Breakdown of Global Anti-Alzheimer's and
Anti-Parkinson's Disease Drugs Market by Region for the Years
2008 & 2012
Table 8: Global Anti-Alzheimer's Disease Drugs Market by
Region for the Period 2007-2015 (Sales in US$ Million)
Table 9: Percentage Breakdown of Global Anti-Alzheimer's
Disease Drugs Market by Region for the Years 2008 & 2012
Table 10: Global Anti-Alzheimer's Disease Drugs Market by
Product Segment for the Period 2007-2015 (Sales in US$
Million)
Table 11: Percentage Breakdown of Global Anti-Alzheimer's
Disease Drugs Market by Product Segment for the Years 2008 &
2012
Table 12: Global Cholinesterase Inhibitors Market by Region
for the Period 2007-2015 (Sales in US$ Million)
Table 13: Percentage Breakdown of Global Cholinesterase
Inhibitors Market by Region for the Years 2008 & 2012
Table 14: Global NMDARA (N-methyl, D-Aspartate Receptor
Antagonists) Market by Region for the Period 2007-2015 (Sales
in US$ Million)
Table 15: Percentage Breakdown of Global NMDARA (N-methyl,
D-Aspartate Receptor Antagonists) Market by Region for the
Years 2008 & 2012
Table 16: Global Anti-Parkinson's Disease Drugs Market by
Region for the Period 2007-2015 (Sales in US$ Million)
Table 17: Percentage Breakdown of Global Anti-Parkinson's
Disease Drugs Market by Region for the Years 2008 & 2012
Table 18: Global Anti-Parkinson's Disease Drugs Market by
Product Segment for the Period 2007-2015 (Sales in US$
Million)
Table 19: Percentage Breakdown of Global Anti-Parkinson's
Disease Drugs Market by Product Segment for the Years 2008 &
2012
Table 20: Global Dopaminergic Agents Market by Region for the
Period 2007-2015 (Sales in US$ Million)
Table 21: Percentage Breakdown of Global Dopaminergic Agents
Market by Region for the Years 2008 & 2012
Table 22: Global Dopamine Agonists Market by Region for the
Period 2007-2015 (Sales in US$ Million)
Table 23: Percentage Breakdown of Global Dopamine Agonists
Market by Region for the Years 2008 & 2012
Table 24: Global Other PD Drugs Market by Region for the
Period 2007-2015 (Sales in US$ Million)
Table 25: Percentage Breakdown of Global Other PD Drugs Market
by Region for the Years 2008 & 2012
Table 26: Percentage Breakdown of Leading Therapeutics by New
Prescription in the North American Alzheimer's Disease Market
- 2005
Table 27: Percentage Breakdown of Leading Brands by
Prescription in the US PD Therapeutics Market -2006
Table 28: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs
Market by Product Segment in the US: 2007-2015 (Sales in US$
Million)
Table 29: Percentage Breakdown of Anti-Alzheimer's and
Anti-Parkinson's Disease Drugs Market by Product Segment in
the US for the Years 2008 & 2012
Table 30: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs
Market by Product Segment in Canada: 2007-2015 (Sales in US$
Million)
Table 31: Percentage Breakdown of Anti-Alzheimer's and
Anti-Parkinson's Disease Drugs Market by Product Segment in
Canada for the Years 2008 & 2012
Table 32: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs
Market by Product Segment in Japan: 2007-2015 (Sales in US$
Million)
Table 33: Percentage Breakdown of Anti-Alzheimer's and
Anti-Parkinson's Disease Drugs Market by Product Segment in
Japan for the Years 2008 & 2012
Table 34: Percentage Breakdown of Leading Brands by New
Prescription in the European Alzheimer's Disease Market - 2005
Table 35: Anti-Alzheimer's and Anti Parkinson's Disease Drugs
Market by Region in Europe: 2007-2015 (Sales in US$ Million)
Table 36: Percentage Breakdown of Anti-Alzheimer's and
Anti-Parkinson's Disease Drugs Market by Region in Europe for
the Years 2008 & 2012
Table 37: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs
Market by Product Segment in Europe: 2007-2015 (Sales in US$
Million)
Table 38: Percentage Breakdown of Anti-Alzheimer's and
Anti-Parkinson's Disease Drugs Market by Product Segment in
Europe for the Years 2008 & 2012
Table 39: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs
Market by Product Segment in Germany: 2007-2015 (Sales in US$
Million)
Table 40: Percentage Breakdown of Anti-Alzheimer's and
Anti-Parkinson's Disease Drugs Market by Product Segment in
Germany for the Years 2008 & 2012
Table 41: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs
Market by Product Segment in France: 2007-2015 (Sales in US$
Million)
Table 42: Percentage Breakdown of Anti-Alzheimer's and
Anti-Parkinson's Disease Drugs Market by Product Segment in
France for the Years 2008 & 2012
Table 43: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs
Market by Product Segment in the UK: 2007-2015 (Sales in US$
Million)
Table 44: Percentage Breakdown of Anti-Alzheimer's and
Anti-Parkinson's Disease Drugs Market by Product Segment in
the UK for the Years 2008 & 2012
Table 45: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs
Market by Product Segment in Italy: 2007-2015 (Sales in US$
Million)
Table 46: Percentage Breakdown of Anti-Alzheimer's and
Anti-Parkinson's Disease Drugs Market by Product Segment in
Italy for the Years 2008 & 2012
Table 47: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs
Market by Product Segment in Spain: 2007-2015 (Sales in US$
Million)
Table 48: Percentage Breakdown of Anti-Alzheimer's and
Anti-Parkinson's Disease Drugs Market by Product Segment in
Spain for the Years 2008 & 2012
Table 49: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs
Market by Product Segment in Rest of Europe: 2007-2015 (Sales
in US$ Million)
Table 50: Percentage Breakdown of Anti-Alzheimer's and
Anti-Parkinson's Disease Drugs Market by Product Segment in
Rest of Europe for the Years 2008 & 2012
Table 51: Anti-Alzheimer's and Anti-Parkinson's Disease Drugs
Market by Product Segment in Rest of World: 2007-2015 (Sales
in US$ Million)
Table 52: Percentage Breakdown of Anti-Alzheimer's and
Anti-Parkinson's Disease Drugs Market by Product Segment in
Rest of World for the Years 2008 & 2012
COMPANIES PROFILED
To order this report:
Alzheimer's and Parkinson's Diseases - A Global Update of Market Trends & Opportunities
http://www.reportlinker.com/p0164262/Alzheimer's-and-Parkinson's-Diseases---A-Global-Update-of-Market-Trends--Opportunities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire
More market research reports here!
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
